CD34 and Hepatic fibrosis: Treatment with cilengitide suppressed the migration of transplanted expanded PB-CD34+ cells into the liver (expanded Hi without cilengitide, 23.5 ± 3.1; expanded Hi with 25 mg/kg cilengitide, 17.3 ± 4.2; expanded Hi with 75 mg/kg cilengitide, 8.8 ± 1.7; Figure 6a) and increase of liver fibrosis in a dose-dependent manner (saline without cilengitide, 9.3 ± 1.4%; saline with 75 mg/kg cilengitide, 12.7 ± 2.6%; expanded Hi without cilengitide, 4.5 ± 1.3%; expanded Hi with 25 mg/kg cilengitide, 5.6 ± 2.2%; expanded Hi with 75 mg/kg cilengitide, 7.9 ± 1.3%; Figure 6c,d).